Abstract: A multi display system (10) includes a plurality of display panels (100) disposed adjacently to each other via a boundary portion (20), and a translucent cover (113) disposed on the plurality of display panels (100). The translucent cover (113) is disposed so as to cover the boundary portion (20) and overlapping with both of the plurality of display panels (100) which are disposed adjacently. The translucent cover (113) is constituted by a supporting portion (113P) which covers at least part of the display panel excluding the boundary portion (20), and a portion which is continuous to the supporting portion (113P) and includes a concave portion (113C) formed on the observer side in a position facing the boundary portion (20).

Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: A light-emitting device capable of ensuring an electric connection between a light-emitting element and an electrode without generating any problem in practical use, by both connecting methods with a solder and a connector, and a lighting device provided with the light-emitting device are provided. The light-emitting device according to the present invention has a plurality of LED chips, and a soldering electrode land and a connector connecting electrode land electrically connected to the chips, on a ceramic substrate. The soldering electrode land is formed of a first conductive material having a function to prevent diffusion to a solder, and the connector connecting electrode land is formed of a second conductive material having a function to prevent oxidation.

Abstract: Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I).

Abstract: A User Equipment (UE) is described. The UE includes a processor and instructions stored in memory that is in electronic communication with the processor. The UE receives signaling to configure the UE with multiple serving cells wherein each of the multiple serving cells is configured with a first uplink/downlink (UL/DL) configuration. The UE also determines a downlink (DL)-reference UL/DL configuration for a serving cell. The UE further sends Physical Downlink Shared Channel (PDSCH) Hybrid Automatic Repeat Request Acknowledgement/Negative Acknowledgement (HARQ-ACK) information based on the DL-reference UL/DL configuration.

Abstract: A deposition mask is used to pattern a thin film 3 on a substrate 10 by depositing deposition particles through a plurality of openings K having a stripe pattern. The deposition mask includes a frame 65; a plurality of mask layers 70 provided in the frame so as to overlap each other; and a support layer 71 provided between the mask layers 70. Each of the mask layers 70 is formed by arranging a plurality of mask wires 72 in a stripe pattern in a tensioned state, and the support layer 71 is formed by arranging a plurality of support wires 74 in a tensioned state so as to cross the mask wires 72. A plurality of gaps 73 in each of the plurality of mask layers 70 overlap each other to form a plurality of through gaps 73a that linearly extend through all of the plurality of mask layers 70. The openings K are formed by the through gaps 73a.

Abstract: An acoustic physiological monitoring system and method wherein the usability for physiological monitoring of time segments of an acoustic signal recording body sounds is determined using frequency analysis. A time segment of the acoustic signal is filtered into a target portion in a target frequency band and a non-target portion in a non-target frequency band. Energies of the target portion and the non-target portion are computed. A usability indicator for the time segment is computed using the energies. The usability of the time segment is determined using the usability indicator. A physiological parameter estimate is selectively calculated using the time segment based on the usability of the time segment. Finally, information based on the physiological parameter estimate is outputted.

Abstract: The present invention is directed to isoxazolopyndine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the isoxazolopyndine compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: A protected transition metal hexacyanoferrate (TMHCF) battery cathode is presented, made from AxMyFez(CN)n.mH2O particles, where the A cations are either alkali or alkaline-earth cations, and M is a transition metal. In one aspect the cathode passivation layer may be materials such as oxides, simple salts, carbonaceous materials, or polymers that form a film overlying the AxMyFez(CN)n.mH2O particles. In another aspect, the cathode passivation layer is a material such as oxygen, nitrogen, sulfur, fluorine, chlorine, or iodine that interacts with the AxMyFez(CN)n.mH2O particles, to cure defects in the AxMyFez(CN)n.mH2O crystal lattice structure. Also presented are TMHCF battery synthesis methods.

Abstract: The present invention makes it possible to (i) obtain a sufficient and uniform luminance on an entire surface, which is irradiated with light, of a light guide plate and (ii) achieve a reduction in cost. LED light source substrates (140a) and (140b ) are each configured to emit light having a first luminance gradient on an edge of a range, to be irradiated with light, which first luminance gradient is smaller than a second luminance gradient of light having a substantially uniform luminance on an entire range to be irradiated with light.

Abstract: The thickness of a rear surface-side inorganic film (9) formed from the same material as that of each of front surface-side inorganic films (11, 13, and 16) and provided at a rear surface side of a resin substrate (10) having a heat resistance is set in a predetermined range with respect to the total thickness of the front surface-side inorganic films (11, 13, and 16) so that the curvature diameter calculated based on the linear elastic modulus, the coefficient of linear expansion, and the thickness of the resin substrate (10); the linear elastic moduli, the coefficients of linear expansion, and the total thickness of the front surface-side inorganic films (11, 13, and 16); and the linear elastic modulus, the coefficient of linear expansion, and the thickness of the rear surface-side inorganic film (9) is 20 mm or more or ?20 mm or less.

Abstract: In an oxide semiconductor layer, a degree of oxidation S1 of a portion located on the side of the gate insulating film, and a degree of oxidation S2 of surface layer portions located in connection regions with source and drain electrodes have a relation of S2<S1 within a range in which the oxide semiconductor layer has predetermined electric resistance, and a degree of oxidation S3 of a surface layer portion of the channel region is made higher than the degrees of oxidation S1, S2 of the other regions within the range in which the oxide semiconductor layer has the predetermined electric resistance, by annealing the oxide semiconductor layer in an oxygen-containing atmosphere after formation of the source electrode and the drain electrode.

Abstract: Methods, systems, and devices provide improved power control for signals used for device-to-device services. In one aspect, a user equipment (“UE”) terminal controls the transmission power of signals used for device-to-device (“D2D”) services based on power control parameters provided by a base station. The UE terminal includes a first power control module for controlling a first transmission power to be applied to signals used for communication with a base station. The UE terminal also includes a second power control module for controlling a second transmission power to be applied to signals used for D2D services. The first and second transmission powers can be determined based on at least one power control parameter received from the base station. The UE terminal also includes a signal transceiver module for transmitting signals used for uplink/downlink communications using the first transmission power and transmitting signals used for D2D services using the second transmission power.

Abstract: A multi-primary-color liquid crystal display device (100) according to the present invention includes a liquid crystal display panel (10) with a pixel made up of red, green, blue and yellow subpixels (R, G, B, Ye) and a signal conversion circuit (20) which converts an input three-primary-color video signal into a four-color video signal. If the three-primary-color video signal supplied to the signal conversion circuit is indicated as (r, g, b) using the grayscale levels r, g and b (each of which is an integer of 0 through 255) of the three primary colors of red, green and blue and if the luminance of the color white displayed by the pixel in response to a three-primary-color video signal indicated as (255, 255, 255) is supposed to be 100%, the signal conversion circuit adjusts the level of the four-color video signal so that when a three-primary-color video signal indicated as (186, 0, 0) is input, the luminance of the color red displayed by the red subpixel becomes equal to or greater than 6.5%.

Abstract: A multi-functional peripheral (MFP”) capable of outputting an image having a wireless communication portion which communicates with an external terminal apparatus wirelessly, a receiving portion which receives a user interface image upon authentication, and a display portion, the user interface image being specified in accordance with a user identification information and a user operation history, and constituting an image displayed on the display portion to operate the MFP directly and/or an image displayed on a terminal-side display portion provided in the external terminal apparatus to operate the MFP, with the MFP executing image output according to user operation received from the operation portion and/or the external terminal apparatus via the wireless communication portion, in a state where the above images are displayed as the user interface image, and based on the user operation history, changing the user interface image specified in order to facilitate operation by the user.

Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.

Abstract: A display device properly corrects chromaticity of display images with achieving high brightness. A liquid crystal display device 10 includes a liquid crystal panel 11 and a backlight unit 12. The liquid crystal display device 10 includes a pair of boards 11a, 11b and a liquid crystal layer 11c formed of liquid crystals that change their optical characteristics by implication of an electric field. The backlight unit 12 exits light toward the liquid crystal panel 11. One of the boards 11a, 11b of the liquid crystal panel 11 includes a color filter 19 including color portions R, G, B, Y each in red, green, blue, yellow. The backlight unit 12 includes LEDs 24 as a light source and each of the LEDs includes an LED chip 24a as a light emission source and a phosphor that is excited by light from the LED chip 24a and emits light. The phosphor includes at least a YAG-based phosphor.

Abstract: Compounds of Formula (I) are disclosed, wherein R1, R2, R3, R4, R5, and R18 are defined herein. The compounds encompassed by Formula (I) include compounds which are HCV NS5B inhibitors and other compounds which can be metabolized in vivo to HCV NS5B inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HCV and the prophylaxis, treatment, or delay in the onset of disease caused by HCV. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.